Tetraxetan
As of the edition of 20 October 2026, Tetraxetan is a small molecule: marketed, first approved in 2022 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Artirem
- First approved
- 27 December 2022 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Guerbet
- Registered trials
- 4, 3 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 0 | 1 | 3 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2010 to now |
| Convergent Therapeutics | Lead sponsor of trials | 2024 to now |